health.wusf.usf.edu1d
Zyn nicotine pouches can be marketed in the U.S., the FDA says. What does this mean?
The FDA said "an extensive scientific review" found the products were found to pose lower risks of cancer and other serious ...
TipRanks on MSN1d
INNOVATE Corp. announces FDA approval of MediBeacon TGFR
INNOVATE Corp. (VATE) announced that the U.S. FDA has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal ...
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the ...
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
Companies That Use Red Dye 3 Respond To Ban
Three companies that use Red Dye No. 3 have responded to Newsweek about the ban on the additive from the nation's food supply, which is due to its potential links to cancer.
What foods use Red Dye No. 3? What to know about the newly banned food coloring
Red Dye No. 3, also known as erythrosine, is a synthetic food dye that gives foods and drinks a bright red color. It is also ...
Smithsonian Magazine1d
FDA Bans Red Dye No. 3 From Food, Beverages and Ingested Drugs, Citing Link to Cancer in Lab Rats
The synthetic additive found in thousands of food products will now be phased out by 2027, but advocates say the agency's ...
FDA Authorization of Flavored Zyn Products Ignores Appeal to Kids and Risks Another Juul
The FDA today has set a dangerous precedent that puts the nation's kids at risk by authorizing the sale of 20 Zyn nicotine ...
PipelineReview.com3d
FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
Topical Gel pre-IND meeting and on track to begin Phase 2a clinical trial in alopecia areata in Q2 2025 Unaudited cash and cash equivalents of approximately $70 million as of December 31, 2024 WARREN, ...